Breast Cancer
Conditions
Brief summary
The Olanzapine Regimen will be superior to the Standard Regimen, as measured by the proportion of patients with Complete Response in the 120 hours following AC chemotherapy.
Interventions
DRUGExperimental drug: Aprepitant
Day 1: 125mg QD; Day 2 to Day 3: 80mg QD
DRUGExperimental drug: Ondansetron
Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose
DRUGExperimental drug: Dexamethasone
Day 1: 12mg QD
DRUGExperimental drug: Olanzapine
Day 1 to Day 5: 10mg QD
DRUGStandard: Aprepitant
Day 1: 125mg QD, Day 2 to Day3: 80mg QD
DRUGStandard: Ondansetron
Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose
DRUGStandard: Dexamethasone
Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD
Sponsors
CCTU
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 74 Years
Healthy volunteers
No
Inclusion criteria
* Chinese patient, female \>=18 and \< 75 years of age. * Patient is diagnosed with early breast cancer. * Patient is naïve to emetogenic chemotherapy moderately or highly emetogenecity. * Patient is scheduled to receive her first course of adjuvant chemotherapy for breast cancer follows: * IV adriamycin 60 mg/m2 + cyclophosphamide 600 mg/m2 * Patient has a predicted life expectancy of \>=4 months. * Patient has ECOG Performance Status of 0-1 * Premenopausal female patients must not be pregnant (documented negative urine pregnancy test). * Patient is able to read, understand and complete study questionnaires and diary, including questions requiring a visual analog scale (VAS) response. * Patient understands the procedures and agrees to participate in the study by giving written informed consent
Exclusion criteria
* Patient with advanced breast cancer. * Patient receiving cisplatin or any other chemotherapy of higher emetogenic potential, except for cyclophosphamide and doxorubicin in the regimens described above. * Patients who are scheduled to receive concurrent radiation as part of their chemotherapy regimen for their malignancy * Patients who experience any vomiting or grade 2-3 nausea per Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v 4.03) in the 24 hours before Day 1 of chemotherapy * Patient has a history of treatment with moderately to highly emetogenic chemotherapy. * Patient has an active infection (e.g., pneumonia, systemic fungal infection) or any uncontrolled disease (e.g., diabetes mellitus, hypertension) which, in the opinion of the investigator, might confound the results of the study or pose unwarranted risk. * Patient with history of glaucoma, dementia, seizures, Parkinson's disease, Neuroleptic Malignant Syndrome (NMS), thromboembolic events. * Patient currently uses any illicit drugs, including marijuana, or has current evidence of alcohol abuse as determined by the investigator. * Patient is mentally incapacitated or has a significant emotional or psychiatric disorder that, in the opinion of the investigator, precludes study entry. * Patients who are regular alcohol drinker or smoker * Patient has a history of any illness that, in the opinion of the investigator, might confound the results of the study or pose unwarranted risk. * Patient has a history of hypersensitivity to aprepitant, ondansetron or dexamethasone. * Patients who have phenylketonuria and abnormal uric acid. * Any investigational drugs taken within 4 weeks prior to Day 1 of cycle 1, and/or is scheduled to receive any investigational drug during the study; * Patient is taking systemic corticosteroid therapy at any dose; however, topical and inhaled corticosteroids are permitted. * Patient has taken a non-registered investigational drug within the 28 days of the Prestudy Visit. * Use, in the 28 days prior to Treatment Day 1, of barbiturates, rifampicin or rifabutin, phenytoin or carbamazepine * Use, in the 7 days prior to Treatment Day 1, of terfenadine, cisapride, astemizole, clarithromycin (azithromycin, erythromycin and roxithromycin are permitted), ketoconazole or itraconazole (fluconazole is permitted), amifostine pimozide 5-HT3 antagonists (ondansetron, granisetron, dolasetron, or tropisetron) phenothiazines (e.g., prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine) butyrophenones (e.g., haloperidol or droperidol) benzamides (e.g., metoclopramide or alizapride) domperidone cannabinoids NK1 receptor antagonists * Use, in the 48 hours prior to Treatment Day 1, of benzodiazepines or opiates, except for single daily doses of lorazepam. s. Use of the following drugs: carbamazepine Fluvoxamine ciprofloxacin dopamine agonists. antiparkinsonian medicinal products medicinal products known to increase QTc interval t. Abnormal laboratory values
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of episodes of nausea in the first 120 hours after first cycle of chemotherapy. | 120 hours | Number of episodes of nausea in the first 120 hours after first cycle of chemotherapy. |
| Number of episodes of vomiting in the first 120 hours after first cycle of chemotherapy. | 120 hours | Number of episodes of vomiting in the first 120 hours after first cycle of chemotherapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of episodes of nausea in the first 120 hours during 4 cycles of chemotherapy. | 120 hours | Number of episodes of nausea in the first 120 hours during 4 cycles of chemotherapy. |
| Number of episodes of vomiting in the first 120 hours during 4 cycles of chemotherapy. | 120 hours | Number of episodes of vomiting in the first 120 hours during 4 cycles of chemotherapy. |
Countries
Hong Kong
Outcome results
None listed